ImmunityBio, Inc. - Common Stock (NQ:IBRX)

10.29 +1.01 (+10.83%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX

March 26, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Reversal Alert: VTIX, MARA, IBRX, BATL, NDRA, EEIQ Gain Momentum as Multi-Sector Catalysts Build

March 26, 2026

Via AB Newswire

Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations

March 26, 2026

NEW YORK, NY - March 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).

Via TheNewswire.com

Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations

March 26, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

March 26, 2026

From ImmunityBio, Inc.

Via Business Wire

Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations

March 24, 2026

NEW YORK, NY - March 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).

Via TheNewswire.com

Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations

March 24, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX

March 24, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on Markets ↗

March 24, 2026

On March 24, 2026, choppy, oil-driven trading and fresh AI disruption fears pressured major U.S. indexes.

Via The Motley Fool

Most active stocks in Tuesday's session ↗

March 24, 2026

Via Chartmill

Why ImmunityBio Stock Is Down More Than 20% Today ↗

March 24, 2026

Perhaps the company's management will be more careful after a third regulatory run-in.

Via The Motley Fool

There are notable gap-ups and gap-downs in today's session. ↗

March 24, 2026

Via Chartmill

ImmunityBio Crashes On FDA Warning Over Anktiva Claims ↗

March 24, 2026

ImmunityBio, Inc. (NASDAQ: IBRX) shares are trading lower after the FDA issued a warning to the company over misleading Anktiva promotions.

Via Benzinga

Why ImmunityBio Stock Is Up More Than 11% Today ↗

March 23, 2026

The young biopharma outfit's growth potential continues to expand.

Via The Motley Fool

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

March 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Stocks Under $10: IBRX, VTIX, NDRA, SMX – 2026 Watch Now!

March 19, 2026

Via AB Newswire

Why Did IBRX Stock Jump 7% In Pre-Market Today? ↗

March 17, 2026

The NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA for more patients. This move broadens its potential use, though the indication is still not FDA-approved.

Via Stocktwits

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

March 17, 2026

From ImmunityBio, Inc.

Via Business Wire

IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗

March 17, 2026

Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement.

Via Stocktwits

Topics ETFs

IBRX Stock Rises 3% Pre-Market: ImmunityBio Reports Breakthrough In NK Cell Therapy Production ↗

March 13, 2026

ImmunityBio also completed a Phase 1 study combining its memory cytokine-enhanced NK cell therapy with ANKTIVA.

Via Stocktwits

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

March 13, 2026

From ImmunityBio, Inc.

Via Business Wire

IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact ↗

March 12, 2026

The company expects global expansion to drive “substantial” revenue starting in 2027.

Via Stocktwits

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗

March 12, 2026

Via MarketBeat

IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst ↗

March 11, 2026

The project relies on an AI-driven manufacturing robot, Leonardo, to automate production and potentially scale NK cell output.

Via Stocktwits

Topics Artificial Intelligence

IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗

March 09, 2026

ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.

Via Stocktwits

Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews ↗

March 09, 2026

The founder cited remarks from a former FDA official and an NIH Director supporting mechanism-based review to speed patient access to therapies like Anktiva.

Via Stocktwits

IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva ↗

March 06, 2026

Investors are focused on Anktiva’s next regulatory step, as ImmunityBio seeks to expand the therapy to BCG-unresponsive papillary bladder cancer.

Via Stocktwits

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗

March 05, 2026

Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility.

Via The Motley Fool

IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗

March 05, 2026

Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases.

Via Stocktwits

IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗

March 04, 2026

Piper Sandler raised the firm's price target on ImmunityBio to $12 from $7 and kept an ‘Overweight’ rating on the shares.

Via Stocktwits

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.